Transgender individuals face unique challenges regarding breast cancer risk and screening due to variations in hormone therapy and surgical interventions. Studies show that transgender women have a higher risk of breast cancer compared to cisgender men but a lower risk than cisgender women, while transgender men generally have a lower risk than cisgender women but higher than cisgender men1 2. Understanding these differences is crucial for developing appropriate screening guidelines and improving health outcomes in this population3 .
Hormone Therapy and Surgery Impact on Breast Cancer Risk
Breast cancer risk in transgender people is influenced primarily by gender-affirming hormone therapy (GAHT) and surgical procedures rather than transgender identity itself3 . In transgender women, estrogen therapy increases breast cancer risk compared to cisgender men, with tumors often resembling those found in cisgender women, particularly estrogen receptor-positive cancers that grow under estrogen influence4 5. Conversely, transgender men receiving testosterone therapy and/or undergoing mastectomy have a reduced risk, although residual breast tissue after surgery may still carry some risk6 7.
Exogenous estrogen promotes tumor growth by stimulating estrogen receptor-positive breast cancers, which are common in transgender women on hormone therapy5 . Testosterone therapy in transgender men is associated with a reduced risk of estrogen receptor-positive breast cancer, possibly due to androgen effects on breast tissue6 . Gender-affirming mastectomy significantly lowers breast cancer risk by removing most breast tissue, but incomplete removal can leave residual tissue that may still develop cancer7 .
Transgender individuals who have not undergone hormone therapy or surgery generally have breast cancer risks similar to their cisgender counterparts8 . Screening and treatment protocols for these individuals align with those for cisgender populations6 .
Key factors influencing breast cancer risk in transgender people:
- Use of exogenous estrogen in transgender women increases breast cancer risk compared to cisgender men4 .
- Estrogen receptor-positive breast cancers are particularly sensitive to hormone exposure5 .
- Testosterone therapy in transgender men reduces risk of estrogen receptor-positive breast cancer6 .
- Gender-affirming mastectomy substantially lowers breast cancer risk by removing breast tissue7 .
- Residual breast tissue after surgery may still pose some risk6 .
💡 Did You Know?
Generally, transgender women have a higher incidence of breast cancer compared to cisgender men but a much lower incidence compared to cisgender women; transgender men have higher rates than cisgender men but lower than cisgender women1 .
Developing Breast Cancer Screening Guidelines
Creating breast cancer screening guidelines for transgender individuals is complex due to limited direct evidence and the influence of hormone therapy duration and surgical history2 3. Current guidelines are primarily extrapolated from cisgender data and expert consensus, highlighting the need for tailored protocols8 .
The US Preventive Services Task Force (USPSTF) draft guidelines include transgender men in mammography recommendations but exclude transgender women despite their elevated risk from estrogen therapy9 . The American College of Radiology (ACR) provides detailed appropriateness criteria stratifying transgender patients by hormone use duration, age, and additional risk factors10 .
Screening recommendations generally stratify risk as follows: cisgender women at highest risk, transgender women on hormone therapy at intermediate risk, and cisgender men at lowest risk4 . For transgender women, screening is typically recommended after at least five years of feminizing hormone use, often starting at age 50, though some guidelines suggest earlier screening for those at higher risk11 12. Mammography is the primary screening modality, with digital breast tomosynthesis (DBT) also considered appropriate in certain cases10 .
For transgender men, screening depends on surgical history. Those who have not undergone mastectomy or have only had breast reduction are advised to follow cisgender female screening guidelines6 10. After gender-affirming mastectomy, routine mammography is generally not recommended due to minimal residual breast tissue; instead, self-examination and clinical monitoring are advised, although evidence for effectiveness is limited6 7.
Screening procedures may induce gender dysphoria, impacting adherence, so individualized screening decisions balancing risk and patient comfort are essential13 .
Summary of screening considerations:
- Screening guidelines are largely based on expert consensus and cisgender data extrapolation8 .
- USPSTF includes transgender men but excludes transgender women in draft mammography guidelines9 .
- Risk stratification places transgender women on hormones at intermediate risk4 .
- Mammography is recommended for transgender women after ≥5 years of hormone use, typically starting at age 5011 .
- Transgender men without mastectomy follow cisgender female screening; post-mastectomy screening is generally not advised6 7.
- Screening may cause gender dysphoria, affecting adherence13 .
| Population Group | Screening Recommendation | Age Threshold | Hormone Use Duration |
|---|---|---|---|
| Transgender women (average risk) | Mammography or DBT may be appropriate | ≥ 40-50 years | ≥ 5 years feminizing hormones10 11 |
| Transgender women (high risk) | Mammography or DBT usually appropriate | ≥ 25-30 years | ≥ 5 years feminizing hormones + risk factors10 |
| Transgender men (no mastectomy) | Follow cisgender female screening guidelines | ≥ 40 years (average risk) | N/A |
| Transgender men (post-mastectomy) | Routine mammography not recommended; self-exam advised | N/A | N/A |
Breast cancer risk in transgender individuals varies widely depending on hormone therapy and surgical history. Awareness and individualized care are essential for effective screening and early detection. 23
Related Stories
Managing Your Personal Health
Breast cancer screening guidelines for transgender individuals remain underdeveloped due to limited evidence and the complexity of risk factors such as hormone therapy duration and surgical history2 3. Individualized risk assessment and shared decision-making between patients and providers are essential until consensus guidelines emerge6 .
Genetic counseling is recommended for transgender individuals with a family history or known genetic predisposition to breast cancer, such as BRCA mutations14 . Self-breast examination and prompt reporting of any breast changes remain important preventive measures for all individuals with breast tissue5 .
“There is consensus that individuals who have undergone top surgery still have a risk of breast cancer because some breast tissue remains after the procedure. This differs from mastectomy, where most or all breast tissue is removed to reduce cancer risk.”
— Scout, Executive Director, National LGBT Cancer Network20
Barriers to screening adherence among transgender people include fear of discrimination, lack of provider knowledge, and gender dysphoria related to screening procedures15 13. Provider education and culturally competent care improve screening rates and health outcomes16 17. Creating a welcoming environment with inclusive language and trained staff can help reduce disparities in breast cancer care18 19.
Tips for managing breast health as a transgender individual:
- Engage in shared decision-making with your healthcare provider regarding hormone therapy and screening6 .
- Seek genetic counseling if you have a family history of breast cancer or known genetic mutations14 .
- Perform regular self-breast examinations and report any abnormalities promptly5 .
- Choose healthcare providers knowledgeable in transgender care to improve screening adherence17 .
- Advocate for culturally safe and inclusive breast cancer screening services18 19.
